Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's announces the launch of over-the-counter store brand equivalent of Prilosec OTC (Omeprazole Delayed-Release)
Tablets, 20 mg in the U.S. Market."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Saunak SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) | Calvin Printer calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
Reddy's announces the launch of over-the-counter
store brand equivalent of Prilosec OTC (Omeprazole
Delayed-Release) Tablets, 20 mg in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. December 11, 2018-
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as
"Dr. Reddy's") announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC)
store-brand equivalent of Prilosec OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market
as approved by the U.S. Food and Drug Administration (USFDA).
OTC Omeprazole Delayed-Release Tablets, 20 mg, is a proton pump
inhibitor used to treat frequent heartburn occurring two or more days per week in adults*.
"This launch illustrates our continued commitment to the OTC
business as well as the depth and breadth of our OTC portfolio," says Milan Kalawadia, Vice President and Head, US OTC and
Speciality Rx businesses, Dr. Reddy's Laboratories. "We look forward to collaborating with our customers to provide
high-quality, affordable alternatives to consumers."
The combined market of Prilosec OTC and private label omeprazole
OTC products had U.S. retail sales of approximately $492 million for the most recent twelve months ending in October 2018 according
Dr. Reddy's Omeprazole Delayed-Release Tablets, 20 mg, is
available in 14 count bottles sold in cartons of 1, 2, or 3 bottles each. Each bottle contains one complete 14-day course of treatment.
Use only as directed.
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context,
the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues. The company assumes no obligation to update any information contained herein.